This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include BJ's Wholesale Club, McKesson and Carpenter Technology
by Zacks Equity Research
BJ's Wholesale Club, McKesson and Carpenter Technology have been highlighted in this Screen of The Week article.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to ease access to difficult anatomy in the peripheral vasculature, thereby serving a wider patient pool.
AmerisourceBergen (ABC) to Buy Germany's PharmaLex for $1.3B
by Zacks Equity Research
AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.
Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption
by Zacks Equity Research
Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.
Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.
3 Stocks With Upgraded Broker Ratings for Robust Returns
by Swayta Shah
As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select BJ, MCK and CRS as these have seen rating upgrades recently.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Globus Medical (GMED) Gains Market Share, Cost Woes Stay
by Zacks Equity Research
Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Charles River (CRL) to Support Cure AP-4's Clinical Trials
by Zacks Equity Research
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
Zimmer Biomet (ZBH) Procedure Recovery Strong, Margin Woe Stays
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong results across the EPD, diagnostics and medical devices businesses are driving Abbott's (ABT) top line.
Abbott (ABT) Debuts Amplatzer Talisman System in Europe
by Zacks Equity Research
Abbott's (ABT) Amplatzer Talisman PFO Occlusion System will enable doctors across Europe to treat people experiencing a patent foramen ovale-associated stroke.
Accuray's (ARAY) Latest Collaboration to Improve Patient Care
by Zacks Equity Research
Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
by Zacks Equity Research
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.
Quest Diagnostics (DGX) Stock Gains on EUA for Monkeypox Test
by Zacks Equity Research
According to Quest Diagnostics (DGX), this test can differentiate monkeypox viral DNA from other non-variola orthopoxviruses in a specimen, helping to enable a faster final diagnosis.
Edward Lifesciences (EW) Gains From New Products Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US
by Zacks Equity Research
Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.